Document is current
Any future updates will be listed below
-
Authors
Mennuni, Mara https://orcid.org/0000-0001-6199-6233
Filograna, Roberta https://orcid.org/0000-0002-6581-9426
Felser, Andrea
Bonekamp, Nina A https://orcid.org/0000-0001-9748-8089
Giavalisco, Patrick https://orcid.org/0000-0002-4636-1827
Lytovchenko, Oleksandr https://orcid.org/0000-0003-1032-2612
Larsson, Nils‐Göran https://orcid.org/0000-0001-5100-996X
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2015‐00418)
Cancerfonden (2018.602)
Knut och Alice Wallenbergs Stiftelse (KAW 2016.0050)
H2020 European Research Council (2016‐741366)
Novo Nordisk Fonden (NNF20OC0063616)
Diabetesfonden (DIA2020‐516)
- License Information
-
More Information
Article History
Received: 14 April 2021
Revised: 12 October 2021
Accepted: 19 October 2021
First Online: 15 November 2021
Conflict of interest
: The IMT1 compound intellectual property is published as WO 2019/057821 and has been licensed by the Max Planck Society and the Lead Discovery Center GmbH. NGL is a scientific founder and holds stock in Pretzel Therapeutics, Inc.
